Literature DB >> 19075685

Development and production of commercial therapeutic monoclonal antibodies in Mammalian cell expression systems: an overview of the current upstream technologies.

Michel Chartrain1, Lily Chu.   

Abstract

This article provides an overview of the upstream technologies used in the industrial production of therapeutic monoclonal antibodies (mAbs) based on the cultivation of mammalian cells. More specifically, in a first section, after a short discussion of relevant biochemical characteristics of antibodies, we review the cell lines currently employed in commercial production and the methods of constructing and isolating production clones. This is followed with a review of the most current methods of commercial scale production and their associated technologies. Selected references and short discussions pertaining to emerging and relevant technologies have been embedded throughout the text in order to give a sense of the overall direction the field is taking.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19075685     DOI: 10.2174/138920108786786367

Source DB:  PubMed          Journal:  Curr Pharm Biotechnol        ISSN: 1389-2010            Impact factor:   2.837


  13 in total

Review 1.  Strategies and challenges for the next generation of therapeutic antibodies.

Authors:  Alain Beck; Thierry Wurch; Christian Bailly; Nathalie Corvaia
Journal:  Nat Rev Immunol       Date:  2010-05       Impact factor: 53.106

2.  4th European Antibody Congress 2008: December 1-3, 2008, Geneva, Switzerland.

Authors:  Alain Beck; Sherif Hanala; Janice M Reichert
Journal:  MAbs       Date:  2009-03-20       Impact factor: 5.857

3.  European Medicines Agency workshop on biosimilar monoclonal antibodies: July 2, 2009, London, UK.

Authors:  Janice M Reichert; Alain Beck; Harish Iyer
Journal:  MAbs       Date:  2009-09-25       Impact factor: 5.857

4.  5th European Antibody Congress 2009: November 30–December 2, 2009, Geneva, Switzerland.

Authors:  Alain Beck; Janice M Reichert; Thierry Wurch
Journal:  MAbs       Date:  2010 Mar-Apr       Impact factor: 5.857

5.  Comprehensive engineering of Escherichia coli for enhanced expression of IgG antibodies.

Authors:  Tomohiro Makino; Georgios Skretas; Tae-Hyun Kang; George Georgiou
Journal:  Metab Eng       Date:  2010-12-03       Impact factor: 9.783

6.  Genetic modification of mesenchymal stem cells to express a single-chain antibody against EGFRvIII on the cell surface.

Authors:  Irina V Balyasnikova; Rosa Franco-Gou; J Michael Mathis; Maciej S Lesniak
Journal:  J Tissue Eng Regen Med       Date:  2010-06       Impact factor: 3.963

7.  CHO cell production and sequence improvement in the 13C6FR1 anti-Ebola antibody.

Authors:  Dean K Pettit; Richard S Rogers; Kelly Arthur; Yan Brodsky; Rutilio H Clark; Chris Crowell; Jane Ennis; Alison Gillespie; Ron Gillespie; Brittney Livingston; Edith Nalbandian; Danielle Pace; Pauline Smidt; Michael Pauly; Ken Timmons; Michael Trentalange; Kevin J Whaley; Larry Zeitlin; James N Thomas
Journal:  MAbs       Date:  2016       Impact factor: 5.857

Review 8.  Challenges of the Nano-Bio Interface in Lateral Flow and Dipstick Immunoassays.

Authors:  Helena de Puig; Irene Bosch; Lee Gehrke; Kimberly Hamad-Schifferli
Journal:  Trends Biotechnol       Date:  2017-09-28       Impact factor: 19.536

9.  Improvement of Biophysical Properties and Affinity of a Human Anti-L1CAM Therapeutic Antibody through Antibody Engineering Based on Computational Methods.

Authors:  Heesu Chae; Seulki Cho; Munsik Jeong; Kiyoung Kwon; Dongwook Choi; Jaeyoung Lee; Woosuk Nam; Jisu Hong; Jiwoo Lee; Seonjoo Yoon; Hyojeong Hong
Journal:  Int J Mol Sci       Date:  2021-06-22       Impact factor: 5.923

10.  Characterization of transferrin receptor-mediated endocytosis and cellular iron delivery of recombinant human serum transferrin from rice (Oryza sativa L.).

Authors:  Deshui Zhang; Hsin-Fang Lee; Steven C Pettit; Jennica L Zaro; Ning Huang; Wei-Chiang Shen
Journal:  BMC Biotechnol       Date:  2012-11-30       Impact factor: 2.563

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.